secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001937653-24-000027
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks Q1 net loss $31.7M, revenue $10M; cash $420.5M, runway into 2H27
--------------------------------------------------------------------------

- Revenue fell to $10.0M from $35.6M YoY due to transfer of zanidatamab responsibilities to Jazz.
- Net loss widened to $31.7M vs $24.4M in Q1 2023; R&D expense decreased 30% to $32.0M.
- Cash resources $420.5M; combined with anticipated milestones, funded into 2H 2027.
- Partner Jazz completed rolling BLA submission to FDA for zanidatamab in BTC; Phase 3 breast cancer trial planned H2 2024.
- On track for two IND submissions in 2024 for ZW191 and ZW171; Dr. Neil Gallagher joined board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765324000027/0001937653-24-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765324000027/zyme-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001937653-24-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer